The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elshafie, A. I.
Right arrow Articles by Rönnelid, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elshafie, A. I.
Right arrow Articles by Rönnelid, J.
The Journal of Immunology, 2007, 178: 5383-5389.
Copyright © 2007 by The American Association of Immunologists, Inc.

Circulating Immune Complexes (IC) and IC-Induced Levels of GM-CSF Are Increased in Sudanese Patients with Acute Visceral Leishmania donovani Infection Undergoing Sodium Stibogluconate Treatment: Implications for Disease Pathogenesis1

Amir Ibrahim Elshafie2,*,{dagger}, Erik Åhlin2,*, Linda Mathsson*, Gehad ElGhazali{ddagger},§ and Johan Rönnelid3,*

* Unit of Clinical Immunology, Uppsala University, Uppsala, Sweden; {dagger} Department of Clinical Pathology and Microbiology, Alribate University Hospital, Khartoum, Sudan; {ddagger} Department of Microbiology and Immunology, University of Khartoum, Sudan; and § King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Infection with Leishmania donovani is associated with IL-10 as well as with GM-CSF. Immune complexes (IC) exert important functions by stimulation of monocytes/macrophage-mediated production of pro- and anti-inflammatory cytokines in rheumatic diseases. In this investigation, we have explored IC-induced cytokine production during Leishmania infection. Sera from 43 patients with visceral leishmaniasis (VL), 17 patients with post-kala-azar dermal leishmaniasis, and 20 healthy Sudanese controls were precipitated with polyethylene glycol (PEG). The PEG precipitates were added to serum-free PBMC for 20 h,whereupon supernatant levels of IL-1beta, IL-6, IL-10, IL-1 receptor antagonist protein, TNF-{alpha}, TNF receptor p75, and GM-CSF were investigated using ELISA. Circulating levels of C1q-binding IC were also measured in the serum samples. PEG precipitates from Leishmania-infected patients induced significantly higher levels of GM-CSF (p = 0.0037) and IL-10 (p < 0.0001), as well as of IL-6 (p < 0.0001) and IL-1 receptor antagonist (p = 0.0238) as compared with PEG precipitates from controls. Patients with acute VL as well as VL patients receiving sodium stibogluconate treatment displayed significantly increased levels of PEG precipitate-induced GM-CSF. The induction of GM-CSF by circulating IC was especially prominent in acute VL patients receiving sodium stibogluconate treatment; ANOVA revealed significant interaction between disease activity and treatment for PEG precipitate-induced levels of GM-CSF (disease activity, p = 0.0006; treatment, p = 0.0005; interaction, p = 0.0046). Parallel associations were determined for C1q-binding immune complexes, but not for any cytokine other than GM-CSF. The importance of IC-induced GM-CSF in leishmaniasis warrants further study.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Visceral leishmaniasis is a disease caused by protozoa of the Leishmania donovani complex. The parasites, which are introduced into their human hosts by sand flies, rapidly invade macrophages where they multiply inside phagolysosomes. Human infections may be asymptomatic or subclinical or may cause a severe disease called visceral leishmaniasis (VL)4 or kala-azar (1, 2, 3). Clinical manifestations of VL include recurrent fever, hepatosplenomegaly, generalized lymphadenopathy, pancytopenia, and anemia. Death occurs in the absence of appropriate chemotherapy (4). Major VL outbreaks have occurred in India and the Sudan in recent years and have killed thousands of people (5). After treatment with sodium stibogluconate, VL patients infected with L. donovani can develop a macular, maculopapular, and nodular rash called post-kala-azar dermal leishmaniasis (PKDL). The incidence of PKDL varies between 50% in the Sudan and 5–10% in India; the reason for this difference is presently unknown (6).

Leishmania parasites exhibit an absolute dependency on macrophages (7), within which they multiply. Macrophage activation with ensuing intracellular parasite killing is the host’s primary defense against Leishmania infection. With Leishmania being recognized as an obligate intracellular parasite of macrophages, studies have demonstrated that specific immunity in VL is mediated by CD4+ Th cells and that disease susceptibility is associated with the inability to produce a macrophage-stimulating cytokine profile (Th1 profile) including IFN-{gamma}, IL-2, and IL-12, while conversely an elevated production of immunosuppressive cytokines such as IL-10 and IL-4 (Th2 profile), as well as high levels of TNF-{alpha}, may be associated with susceptibility (8, 9).

The hemopoietic growth factor GM-CSF has many stimulatory effects on monocytes/macrophages that are helpful during intracellular infections, such as enhancing phagocytic and metabolic functions and the release of other proinflammatory cytokines (10). Addition of GM-CSF to human monocytes in vitro increases their leishmanicidal effects (11), and, when mice infected with L. donovani were treated with murine GM-CSF, they showed increased leishmanicidal activity, as well as leukocytosis and myelomonocytic accumulation in infected viscera (12). In a small placebo-controlled study, GM-CSF-treated Leishmania chagasi-infected patients had a significantly reduced number of secondary infections, along with increased neutrophil counts (13). The production of GM-CSF is increased during infection in the liver of L. donovani-infected BALB/c mice (12) and in mouse bone marrow stromal macrophages (7) findings arguing for a counterregulatory and potentially disease-limiting effect of Leishmania infection-induced GM-CSF production. This hypothesis is also sustained by the fact that Leishmania parasites genetically engineered to produce GM-CSF within their phagosomes showed poor survival within macrophages that had been activated by the GM-CSF to produce an array of proinflammatory cytokines (14). Recently, L. donovani amastigote Ags have been reported to induce GM-CSF production in mouse peritoneal macrophages both in vitro and in vivo (15).

Leishmania-infected patients have increased levels of circulating Clq-binding immune complex (CIC) (16, 17, 18, 19, 20, 21), which contain Leishmania Ags (22, 23). Such immune complexes (IC) might affect disease progression and disease outcome through induction of pro- or anti-inflammatory cytokines, in analogy to our earlier findings in rheumatic diseases. We have previously demonstrated that polyethylene glycol (PEG)-precipitated IC from sera of systemic lupus erythematosus (SLE) patients induce IL-6 and IL-10 when added to PBMC (24). Purified cryoglobulins from patients with multiple myeloma and Waldenström’s macroglobulinemia induced TNF-{alpha} and IL-10 (25), and IC from rheumatoid arthritis synovial fluids induce TNF-{alpha} (26). We have also reported IC-induced cytokine production to depend on monocytes in the PBMC preparations and to require the expression of Fc{gamma}RIIa on the monocyte surface (24, 25, 26, 27).

VL patients exhibit kidney alterations in the form of interstitial nephritis (28) as well as glomerulonephritis (29, 30). Such changes might be mediated through IC-induced cytokines such as IL-10 or GM-CSF. GM-CSF is of importance in T cell/monocyte-mediated forms of kidney damage and experimental glomerulonephritis (31, 32). IC-induced IL-10 was recently demonstrated to be instrumental for disease progression in experimental Leishmania infection in mice (33).

In this article, we have studied the cytokine-inducing effects of IC from clinically well-characterized patients with Leishmania infection. By measuring a panel of pro- and anti-inflammatory cytokines, including naturally occurring cytokine inhibitors, we found increased IC-induced production of pro- and anti-inflammatory cytokines in Leishmania-infected Sudanese patients as compared with healthy controls. Quite unexpectedly, the IC-induced production of GM-CSF was substantially increased, especially from patients with active VL who had recently started sodium stibogluconate treatment. Possible consequences of this finding are discussed.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Study area, patients, and establishment of diagnosis

This study was conducted at Tabarakalla rural hospital in Gadarif state, along the lower Atbara river in Gallabat Province, eastern Sudan. The area is located ~70 km southeast from the Gadarif town. It is endemic for L. donovani and its main vector in that area is Phlebotomus orientalis (34). Patients enrolled in the study mainly came from the Tabarakalla and Barbar Elfogara villages, endemic areas with a high prevalence of both VL and PKDL.

A detailed clinical history was obtained, including tribe, residence, occupation, marital status, medical treatment, abdominal pain, vomiting, nausea, previous history of bleeding tendency, urinary tract infection and insect bites, and family history of VL, hypertension, or diabetes mellitus. Particular emphasis was made regarding any previous form of leishmaniasis. Subjects were questioned about their ethnic and geographic origin and were examined for clinical manifestations of VL. A general clinical examination was conducted with particular reference to hepatosplenomegaly, enlargement of lymph nodes, and recurrent fever for more than 1 mo. Liver size was measured in the midclavicular line from the costal margin; the spleen size was assessed by measuring the distance between the costal margin in the anterior axillary line to the tip of the spleen. Lymphadenopathy was classified as "localized" if only found at one site and "generalized" if found at two or more sites. The oral and nasal mucous membranes were examined for evidence of mucosal leishmaniasis. Thick and thin blood films for detection of Plasmodium parasites were examined from all individuals who either had fever, looked ill, or had splenomegaly, and those with positive blood films for malaria were excluded.

An inguinal lymph node aspiration was performed on those clinically suspected of having VL (i.e., all individuals with fever for >2 mo, left upper quadrant pain, lymphadenopathy, splenomegaly, or wasting). Those with a negative result underwent bone marrow aspiration from the superior posterior iliac crest. The smears were fixed with methanol, stained with Giemsa, and examined using an oil-immersion lens. Severely ill VL patients from the study area admitted to hospitals because of need for further medical care were classified as acute VL. Patients not severely ill and treated as outpatients with daily injections of sodium stibogluconate were classified as subacute VL. Treated patients received daily i.v. injections of sodium stibogluconate, 20 mg/kg for 30 days, with a mean of 4 days between the start of treatment and blood sampling. PKDL was diagnosed on clinical grounds, on the appearance and distribution of the rash after treatment in previously diagnosed VL patients. There are no laboratory tests for diagnosing PKDL. The interval between VL and the occurrence of PKDL and the duration of the rash was estimated from the patients’ histories. Additional acute VL patients from the study area who had been treated with sodium stibogluconate were recruited from the treating hospital.

Venous whole blood was drawn from the Leishmania-infected patients and their healthy controls. Samples were drawn before treatment in newly diagnosed patients. Sera were separated by centrifugation within 2 h of collection. Serum samples were stored and transported frozen in liquid nitrogen until analyzed in Uppsala, Sweden. Sera were obtained from 43 patients with VL (33 males and 10 females; mean age, 21 years), 17 patients with PKDL (13 males and 4 females; mean age, 10 years), and 20 healthy controls (14 male and 6 females; mean age, 21 years).

Ethical approval for this study was obtained from the Ethical Committee of the Faculty of Medicine, University of Khartoum, from the Ministry of Health at Gadarif State, and from the Ethical Committee at Uppsala University. Informed consent was obtained from all of the adults who participated in the study. For young children, consent was obtained from their parents.

PEG precipitation of IC

Serum samples were thawed and immediately mixed with an equal volume of 5% PEG 6000 with 0.1 M EDTA and left to stand at 4°C overnight before the precipitates were purified and washed in a single-step centrifugation procedure described previously (35). Briefly, 1 ml of PBS containing 5% human serum albumin (HSA; Baxter) and 2.5% PEG 6000 (PBS-HSA-PEG) was added to 1.5 ml of autoclaved Eppendorf tubes. Plastic cylinders made out of 5-ml autoclaved pipette tips, by cutting ~1.5 cm of the tips, were introduced into the Eppendorf tubes containing PBS-HSA-PEG. Serum that had been precipitated overnight was diluted 1/3 in RPMI 1640 containing 2.5% PEG 6000 and then placed on top of the PBS-HSA-PEG in the pipette tips. An interface was then formed with the less dense, red RPMI 1640 solution on top. The tubes were centrifuged at 2100 x g at 4°C for 20 min, whereby the precipitates in the upper 2.5% PEG-RPMI 1640 solution were centrifuged down to the bottom of the Eppendorf tube. The remaining PBS-HSA-PEG solution was removed and the pellet containing PEG-precipitated IC was resolved in ice-cold sterile PBS of the original serum volume. The diluted PEG precipitates were placed on ice until used in cell culture experiments.

Preparation of mononuclear cells and cell cultures

Buffy coats were obtained from healthy blood donors and diluted 1/4 in sterile PBS at room temperature, before separation on Ficoll-Paque (GE Health Care). After two washes in PBS, PBMC were diluted to 1 x 106 cells/ml in RPMI 1640 supplemented with 300 mg/ml L-glutamine, 1% HEPES, 1% penicillin-streptomycin, and 4% Ultroser G (Flow Laboratories). This serum-free system had been optimized for studies of IC-induced cytokine responses. We had found earlier that medium supplemented with 4% Ultroser G (Flow Laboratories) more efficiently sustains IC-induced cytokine production as compared with other serum substitutes (25, 26, 36). PEG precipitates (10% v/v) were added to the cell cultures directly after PBMC preparation and within 2 h of PEG precipitation. Cell cultures were performed in 300-µl volumes in sterile flat-bottom 96-well plates for 20 h before harvest of the supernatants.

Our experience of different responder cell populations used for IC stimulation is that PBMC populations might either be good responders to IC or show generally low or generally activated cytokine production without substantial effects of added IC. Due to such variations, two PBMC donors were used as responder cells in parallel in each experiment except in the Fc{gamma}R blockade experiment. The results presented are from the PBMC donor giving the strongest net response following IC stimulation.

Measurement of cytokines in supernatants and serum levels of CIC

Measurement of TNF-{alpha}, IL-1beta, IL-10, TNF receptor p75 (TNF-Rp75), IL-10, GM-CSF, and IL-1 receptor antagonist (IL-1ra) in supernatants was performed using ELISA. All cytokine ELISAs had been established in the laboratory for the measurement of IC-induced cytokine responses in vitro and are described elsewhere (24, 25, 36) using biotinylated detection Abs, streptavidin-HRP (R&D Systems), and 3,3'-5,5'-tetramethylbenzidine (DakoCytomation) as substrate. The Abs and recombinant cytokine standards used in the assay were purchased from R&D Systems except for IL-10, TNF-Rp75 (both from BioSource International) and IL-6 (Mabtech). As capture, mouse mAbs MAB610 (2.0 µg/ml, for TNF-{alpha}), MAB601 (2.0 µg/ml, for IL-1beta), 897C2G9 (4 µg/ml, for TNF-Rp75), MAB615 (2.0 µg/ml; for GM-CSF), and MAB280 (5 µg/ml, for IL-1ra) were used. For detection, biotinylated polyclonal goat Abs BAF210 (0.1 µg/ml for TNF-{alpha}), BAF201 (2.5 µg/ml, for IL-1beta), BAF280 (25 ng/ml, for IL-1ra), and mouse mAbs 911B3H10 (0.4 µg/ml, for TNF-Rp75) and BAM215 (1.0 µg/ml, for GM-CSF) were used. For IL-10, paired F(ab')2 Abs (Flexia; BioSource International) were used at concentrations recommended by the manufacturer. For IL-6, the capture (13A5) and the detecting Abs (39C3) were used at concentrations of 1 and 2 µg/ml, respectively.

CIC was measured using a commercial kit (The Binding Site) according to the manufacturer’s instructions.

Fc{gamma}R blocking experiments

Anti-Fc{gamma}RII mAb (IV.3 (Fab); Medarex) or anti-Fc{gamma}RIII (3G8 (F(ab')2); Medarex) were added to the cells and left to stand at 4°C for 30 min before addition of dissolved PEG precipitates. For this specific experiment, frozen and subsequently thawed PEG precipitates were used. The Ab concentration used was 1.5 µg/ml; preliminary experiments had shown an equivalent blocking effect using either 1.5 or 4 µg/ml. Ab IV.3 has earlier been shown to react specifically with Fc{gamma}RIIa (37, 38).

Statistics

An unpaired t test was used for comparisons between groups in unpaired design, a paired t test for investigating the effects of Fc{gamma}R blockade in paired design, and Pearson’s moment product correlation test was used to determine correlations, with Fisher’s R-to-S conversion to determine p values. The ratios between pro- and anti-inflammatory cytokines were determined individually for each patient or control, and the distribution of individual ratios were thereafter compared between the groups in unpaired design. Two-way ANOVA was used to investigate the combined effects of disease activity and ongoing sodium stibogluconate treatment on levels of CIC and IC-induced cytokines. Values of p < 0.05 were considered to be significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
PEG-precipitated serum IC from L. donovani-infected patients induce pro- and anti-inflammatory cytokines

PEG precipitates from Leishmania-infected patients induced higher mean levels of all investigated cytokines as compared with healthy Sudanese controls (Table I). This was most evident for IL-6 (p < 0.0001; Fig. 1a), IL-10 (p < 0.0001; Fig. 1b) and GM-CSF (p = 0.0037; Fig. 1c), but did not reach significance for IL-1beta (p = 0.052) and for TNF-{alpha} (p = 0.065; data not shown).


View this table:
[in this window]
[in a new window]

  		Table I. Differences between subgroups of Leishmania-infected patientsa

 

Figure 1
View larger version (14K):
[in this window]
[in a new window]

  		FIGURE 1. Cytokine responses to PEG-precipitated IC from 60 Sudanese Leishmania-infected patients and 20 Sudanese controls. PEG precipitates were added to serum-free PBMC cultures and after 20 h supernatant levels of IL-6 (a), IL-10 (b), and GM-CSF (c) were investigated by ELISA.

 
When ratios between corresponding pro- and anti-inflammatory cytokines were calculated, the PEG IC-induced profile was more proinflammatory among the Leishmania patients as compared with the Sudanese controls (p = 0.0474 for TNF-{alpha}:TNF-Rp75 and p = 0.0008 for IL-1beta:IL-1ra, respectively; Table I). The same was true for the calculated GM-CSF:IL-10 ratio (p = 0.0014; Table I).

Data are presented for the PBMC donor having the strongest net PEG IC-induced cytokine responses. Results did however correlate strongly between the two donors, with r values of 0.76, 0.86, and 0.71 for IL-6, IL-10, and GM-CSF, respectively (all p < 0.0001; data not shown).

GM-CSF is selectively induced by PEG precipitates from patients with acute VL and VL patients receiving sodium stibogluconate therapy

When all VL and PKDL patients were compared, there was no significant difference in the levels of any of the investigated cytokines induced by PEG-precipitated IC. Subdivision of the VL patients revealed significantly higher GM-CSF levels induced by PEG precipitates from acute VL patients as compared with patients with subacute disease (p = 0.0311) and among VL patients receiving sodium stibogluconate therapy as compared with untreated patients (p = 0.0060; Table I). This finding was GM-CSF specific, because none of the other pro- or anti-inflammatory cytokines or cytokine inhibitors exhibited such differences between the VL subgroups (Table I).

High levels of CIC characterize patients with acute VL and VL patients receiving sodium stibogluconate therapy

Patients with acute VL had highly elevated levels of CIC (p = 0.0077; Table I and Fig. 2) as compared with patients with subacute VL. CIC levels were also significantly higher in VL patients receiving sodium stibogluconate therapy than in nontreated VL patients. No such differences were evident in the general comparison between all Leishmania-infected patients and controls, or between VL and PKDL patients (Table I).


Figure 2
View larger version (11K):
[in this window]
[in a new window]

  		FIGURE 2. Differences in C1q-binding CIC between patients with acute VL (n = 18) and subacute VL (n = 24). One patient with subacute VL is missing due to lack of serum.

 
Disease severity and treatment interact to induce CIC and PEG-IC-stimulated levels of GM-CSF in VL patients

The comparisons described above had demonstrated higher CIC levels among patients with nontreated VL and VL patients on sodium stibogluconate therapy. The same was true for GM-CSF, but not for any of the other investigated cytokines. We therefore performed two-way ANOVA analyses for VL patients with disease activity and ongoing therapy as independent variables and CIC and cytokine responses as dependent variables. Elevated CIC levels could then be associated with acute VL (p = 0.0004) and with ongoing sodium stibogluconate therapy (p = 0.0025). There was also an interaction between disease activity and ongoing therapy (p = 0.0255), indicating that active disease and ongoing therapy synergized to predispose to high CIC levels (Fig. 3a). Almost identical results emerged when PEG IC-induced levels of GM-CSF instead were used as a dependent variable in ANOVA (disease activity, p = 0.0006; therapy, p = 0.0005; interaction, p = 0.0046; Fig. 3b). None of the other investigated cytokines, including TNF-Rp75 and IL-1ra, exhibited any such association with either disease activity or ongoing treatment.


Figure 3
View larger version (14K):
[in this window]
[in a new window]

  		FIGURE 3. The effect of treatment and activity of disease on CIC and GM-CSF levels in VL patients. Mean levels of C1q-binding CIC (a) and PEG (b) precipitate-induced levels of GM-CSF in patients with VL with patients simultaneously grouped according to disease activity and therapy. The statistical results obtained from two-way ANOVA measurement with disease activity and treatment as independent variables and CIC and PEG IC-induced levels of GM-CSF as dependent variables are presented. Bars, SD. CIC data on one patient with subacute VL is missing due to lack of serum.

 
Strong correlation between CIC and PEG IC-induced levels of GM-CSF in acute VL patients on sodium stibogluconate therapy

There was, as expected, a positive relationship between PEG IC-induced levels of cytokines and CIC levels in general, but the degree of correlation was strongest for GM-CSF. The highest degree of correlation was among acute VL patients and among VL patients receiving sodium stibogluconate therapy (Table II). One exception from this general pattern was the high degree of correlation between CIC and PEG IC-induced levels of IL-10 among subacute VL patients (Table II).


View this table:
[in this window]
[in a new window]

  		Table II. Correlation between CIC and cytokine responsesa

 
Comparisons of IC-induced cytokine responses in Leishmania-infected patients with different clinical and demographic characteristics

When we compared IC-induced cytokine responses to the dichotomous demographic variables sex, marital status, predominant indoor or outdoor occupation and family history of VL, and to the occurrence of fever, abdominal distension, abdominal pain, vomiting, nausea, bleeding tendency, paleness, jaundice, lymph node enlargement, palpable spleen and palpable liver, only a few weakly significant differences appeared. Patients presenting with abdominal distension and nausea showed higher IC-induced production of IL-6 (p = 0.0400 and 0.0371, respectively; data not shown), whereas IC from patients jaundiced at the time of blood sampling induced higher levels of GM-CSF (p = 0.0211; data not included). Age recorded as a continuous variable only showed a weak negative correlation to IC-induced production of TNF-{alpha} (r = –0.257, p = 0.0435; data not shown). No other variables showed any statistical correlations or association to levels of IC or IC-induced cytokines.

Induction of GM-CSF from PBMC by PEG precipitates from L. donovani-infected patients is dependent on Fc{gamma}RIIa

When responder cells were incubated with Fab or F(ab')2 of Abs blocking Fc{gamma}RIIa and Fc{gamma}RIII, we obtained a significant decrease in the production of GM-CSF (p = 0.0321) as compared with cell cultures without any FcR blockade. Blockade of Fc{gamma}RIII, on the other hand, increased GM-CSF production (p = 0.0088). The effects of Fc{gamma}R blockade was smaller on PEG precipitates obtained from four healthy Sudanese controls, especially for Fc{gamma}RIIa.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
In this investigation, we have demonstrated that PEG-precipitated IC from Leishmania-infected patients induce the proinflammatory cytokines GM-CSF and IL-6, as well as the immunosuppressive or anti-inflammatory cytokines IL-10 and IL-1ra. Generally, the effect of Leishmania-derived IC was more proinflammatory than anti-inflammatory when the responses between individual cytokines and their natural inhibitors were compared. There was no overt difference in cytokine responses induced by PEG-precipitated IC from VL or PKDL patients. VL patients with severe disease and VL patients with ongoing sodium stibogluconate therapy exhibited significantly increased levels of IC-induced GM-CSF, closely correlated to levels of C1q-binding CIC# measured by conventional techniques. When applying two-way ANOVA, both disease severity and recently initiated sodium stibogluconate therapy were in a synergistic fashion associated with IC-induced levels of GM-CSF, but not with any of the other investigated cytokines. An almost identical association was evident for C1q-binding CIC.

A number of previous studies have reported increased levels of CIC containing parasite Ags in human Leishmania infection (16, 17, 18, 19, 20, 21, 22, 23). The cytokine GM-CSF induced by Leishmania Ags (15) might be either beneficial by activating macrophages to become leishmanicidal (11, 12) or detrimental by stimulating inflammation through a T cell-driven delayed-type hypersensitivity response, thereby facilitating Leishmania-associated kidney involvement (31, 32).

Earlier longitudinal studies in treated VL patients have demonstrated decreasing CIC levels after initiation of sodium stibogluconate therapy (18, 39), contrasting with our cross-sectional study. This difference might be due to divergent time intervals between institution of therapy and blood sampling. Whereas the earlier study (18) compared levels of CIC before and 1.5 mo after the start of therapy, our patients were sampled during the very first days (median 4 days) after treatment began. We hypothesize that very early during therapy a massive number of parasites are destroyed, releasing Ag into the circulation and increasing the load of CIC-containing parasite Ags, in analogy with the Jarish-Herxheimer reaction observed after initiation of syphilis therapy (40). We hypothesize that VL patients with active disease have more parasites than do VL patients with subacute disease. Such an hypothesis might account for the differences observed in CIC levels and PEG IC-induced levels of GM-CSF between patients with severe and subacute VL and also for the synergistic effects between IC responses, on the one hand, and disease activity and ongoing therapy on the other, as indicated in our ANOVA analyses.

Our findings of markedly increased levels of CIC and IC-induced GM-CSF very early after sodium stibogluconate treatment also prompt for careful short-term longitudinal studies of IC responses the very first days after treatment begins, aiming to correlate those IC responses to clinical symptoms such as skin rash and signs of transient or permanent kidney involvement.

In a parallel study, we have examined a panel of clinical laboratory measures of kidney and liver function in Leishmania-infected patients (41). Our analysis revealed that cystatin C, a marker of kidney function that is superior to creatinine due to its independency of muscle mass, closely correlates with CIC levels and with IC-induced levels of GM-CSF but not with other investigated cytokines. Collectively, these two investigations therefore argue for a role of CIC and IC-induced impairment of kidney function in VL patients with severe disease, possibly in association with newly instituted sodium stibogluconate treatment, in concordance with the correlation of CIC and creatinine observed in canine leishmaniasis (42). Using a mouse knockout model, GM-CSF has also been demonstrated to be necessary for the development of T cell/macrophage-mediated crescentic glomerulonephritis (32).

A number of earlier studies have implicated IL-10 in the immune suppression associated with Leishmania infection, arguing either for Th2 response (43) or regulatory T cells (44) as the main source of immune-suppressive IL-10. In three recent investigations of experimental leishmaniasis in mice, IC are implicated in the production of IL-10 (33, 45, 46) in analogy with our own studies of SLE (24) and cryoglobulinemia (25). The idea that IC should have immune-suppressive function in Leishmania infection is not new; Sehgal and coworkers (19) postulated such a relationship >20 years ago and our findings present a possible explanation for such an association.

We are also intrigued by the divergent propensity to PKDL development between VL patients from the Sudan and India (6). Hypothetically, the tendency to develop PKDL might depend on the single individual’s unique response to sodium stibogluconate treatment as a result of parasite load, genetic predisposition, environmentally acquired traits, or a combination of such factors. Gasim et al. (47) have reported that higher serum levels of IL-10 and keratinocyte expression of IL-10 in VL patients predict PKDL development. Patients who later developed PKDL also had significantly larger spleens (47), possibly reflecting a heavier load of parasites or CIC-containing parasite Ags sequestered in the spleen. Theoretically, the stronger IL-10 response in pre-PKDL patients might reflect IC-induced cytokine production, but Gasim et al. (47) did not investigate whether increased amounts of IC were found in skin biopsies or in the circulation.

In this study, as well as in our previous studies (24, 25, 26, 27), IC-induced cytokine production was partially dependent on Fc{gamma}RIIa. In the present study, the decrease in GM-CSF production after Fc{gamma}RIIa blockade was small (mean, 25.4% decrease). This might be due to the use of frozen and thawed PEG precipitates in this specific experiment. We have found earlier that freshly prepared PEG precipitates from rheumatoid arthritis and SLE patients induce higher levels of cytokines as compared with frozen/thawed PEG precipitates where IC may have been destroyed. Since the Fc{gamma}RIIa receptor is primate specific and not appearing in rodents (48), our findings argue that investigations of the effects of IC in Leishmania infection should be performed in human experimental systems. We believe that the stimulatory effect of the Fc{gamma}RIII blockade is independent of IC because it is seen also in PEG precipitates from control individuals in this investigation, in healthy control IC (27), as well as with cultures with monomeric IgG (24). On the contrary, we have not ruled out a significant effect of Fc{gamma}RIII since our PBMC cultures contain monocytes with very low Fc{gamma}RIII expression (for discussion, see Ref. 26). The selective importance of Fc{gamma}RIII in inflammatory macrophages therefore has to be investigated separately.

We have in this article demonstrated that PEG-precipitated IC from Sudanese patients with leishmaniasis induce pro- and anti-inflammatory cytokines. Notably, IC-induced GM-CSF levels are increased in acute VL patients and in VL patients with ongoing sodium stibogluconate treatment and correlate to a high degree with CIC levels. Our findings support recent studies indicating the significance of IC/cytokine-mediated mechanisms in Leishmania infection in mice (33, 45, 46) by also showing a possible impact of IC-mediated cytokine production in human Leishmania infection.


   Acknowledgments
 
We are thankful to Prof. A. Ashmage for facilitating the work of Amir Elshafie in Uppsala. We express our gratitude to all doctors at the Gadarif Ministry of Health and at Tabarakalla rural hospital who helped us and aided the collection of patient samples. Especially we mention the contributions of Dr. Muzamil and Dr. Ahmad Mudawi. We thank Associate Prof. R. A. Harris for linguistic advice. Above all, we appreciate the help from all Sudanese patients, some of them very ill at the time of sampling and who are no longer able to experience our thankfulness.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This investigation was supported by grants from the Swedish Society of Medicine, King Gustav V’s 80-years Fund, Swedish League against Rheumatism, Ugglas Foundation, Groschinsky Foundation, Viberg Foundation, and Swedish Fund for Research Without Animal Experiments. Back

2 A.I.E. and E.A. contributed equally. Back

3 Address correspondence and reprint requests to Dr. Johan Rönnelid, Unit of Clinical Immunology, Rudbeck Laboratory C5, Uppsala University, SE-75185 Uppsala, Sweden. E-mail address: johan.ronnelid{at}klinimm.uu.se Back

4 Abbreviations used in this paper: VL, visceral leishmaniasis; CIC, circulating immune complex; HSA, human serum albumin; IC immune complex; IL-1ra, IL-1 receptor antagonist protein; PEG, polyethylene glycol; PKDL, post-kala-azar dermal leishmaniasis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TNF-Rp75, TNF receptor p75. Back


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Southgate, B. A., P. E. Manson-Bahr. 1967. Studies in the epidemiology of East African leishmaniasis: 4. The significance of the positive leishmanin test. J. Trop. Med. Hyg. 70: 29-33. [Medline]
  2. Badaro, R., T. C. Jones, E. M. Carvalho, D. Sampaio, S. G. Reed, A. Barral, R. Teixeira, W. D. Johnson, Jr. 1986. New perspectives on a subclinical form of visceral leishmaniasis. J. Infect. Dis. 154: 1003-1011. [Medline]
  3. Badaro, R., T. C. Jones, R. Lorenco, B. J. Cerf, D. Sampaio, E. M. Carvalho, H. Rocha, R. Teixeira, W. D. Johnson, Jr. 1986. A prospective study of visceral leishmaniasis in an endemic area of Brazil. J. Infect. Dis. 154: 639-649. [Medline]
  4. Pearson, R. D., A. Q. Sousa. 1996. Clinical spectrum of leishmaniasis. Clin. Infect. Dis. 22: 1-13. [Medline]
  5. Seaman, J., A. J. Mercer, E. Sondorp. 1996. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int. J. Epidemiol. 25: 862-871. [Abstract/Free Full Text]
  6. Zijlstra, E. E., A. M. Musa, E. A. Khalil, I. M. el-Hassan, A. M. el-Hassan. 2003. Post-kala-azar dermal leishmaniasis. Lancet Infect. Dis. 3: 87-98. [Medline]
  7. Cotterell, S. E., C. R. Engwerda, P. M. Kaye. 2000. Leishmania donovani infection of bone marrow stromal macrophages selectively enhances myelopoiesis, by a mechanism involving GM-CSF and TNF-{alpha}. Blood 95: 1642-1651. [Abstract/Free Full Text]
  8. Liew, F. Y., S. Millott, C. Parkinson, R. M. Palmer, S. Moncada. 1990. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J. Immunol. 144: 4794-4797. [Abstract]
  9. Sang, D. K., J. H. Ouma, C. C. John, C. C. Whalen, C. L. King, A. A. Mahmoud, F. P. Heinzel. 1999. Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis. J. Infect. Dis. 179: 743-746. [Medline]
  10. Jones, T. C.. 1996. The effect of granulocyte-macrophage colony stimulating factor (rGM-CSF) on macrophage function in microbial disease. Med. Oncol. 13: 141-147. [Medline]
  11. Al-Zamel, F., F. J. Al-Shammary, S. El-Shewemi, R. Soliman. 1996. Enhancement of leishmanicidal activity of human macrophages against Leishmania major and Leishmania donovani infection using recombinant human granulocyte macrophage colony stimulating factor. Zentralbl. Bakteriol. 285: 92-105. [Medline]
  12. Murray, H. W., J. S. Cervia, J. Hariprashad, A. P. Taylor, M. Y. Stoeckle, H. Hockman. 1995. Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J. Clin. Invest. 95: 1183-1192. [Medline]
  13. Badaro, R., C. Nascimento, J. S. Carvalho, F. Badaro, D. Russo, J. L. Ho, S. G. Reed, W. D. Johnson, Jr, T. C. Jones. 1994. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J. Infect. Dis. 170: 413-418. [Medline]
  14. Dumas, C., A. Muyombwe, G. Roy, C. Matte, M. Ouellette, M. Olivier, B. Papadopoulou. 2003. Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice. Infect. Immun. 71: 6499-6509. [Abstract/Free Full Text]
  15. Singal, P., P. P. Singh. 2005. Leishmania donovani amastigote components-induced colony-stimulating factors production. Parasitol. Int. 54: 9-20. [Medline]
  16. Pearson, R. D., J. E. de Alencar, R. Romito, T. G. Naidu, A. C. Young, J. S. t. Davis. 1983. Circulating immune complexes and rheumatoid factors in visceral leishmaniasis. J. Infect. Dis. 147: 1102[Medline]
  17. Kharazmi, A., H. R. Rezai, M. Fani, N. C. Behforouz. 1982. Evidence for the presence of circulating immune complexes in serum and C3b and C3d on red cells of kala-azar patients. Trans. R. Soc. Trop. Med. Hyg. 76: 793-796. [Medline]
  18. Kager, P. A., C. E. Hack, A. J. Hannema, P. H. Rees, A. E. von dem Borne. 1982. High C1q levels, low C1s/C1q ratios, and high levels of circulating immune complexes in kala-azar. Clin. Immunol. Immunopathol. 23: 86-93. [Medline]
  19. Sehgal, S., B. K. Aikat, A. G. Pathania. 1982. Immune complexes in Indian kala-azar. Bull. World Health Organ. 60: 945-950. [Medline]
  20. Galvao-Castro, B., J. A. Sa Ferreira, K. F. Marzochi, M. C. Marzochi, S. G. Coutinho, P. H. Lambert. 1984. Polyclonal B cell activation, circulating immune complexes and autoimmunity in human American visceral leishmaniasis. Clin. Exp. Immunol. 56: 58-66. [Medline]
  21. Makni, S., K. Ayed, M. Ben Said, M. S. Ben Rachid. 1989. Study of circulating immune complexes during the evolution of visceral Mediterranean leishmaniasis. Ann. Trop. Med. Parasitol. 83: 349-355. [Medline]
  22. Mary, C., G. Ange, S. Dunan, D. Lamouroux, M. Quilici. 1993. Characterization of a circulating antigen involved in immune complexes in visceral leishmaniasis patients. Am. J. Trop. Med. Hyg. 49: 492-501. [Abstract/Free Full Text]
  23. Chakraborti, T., D. Sarkar, D. K. Ghosh. 2003. Immune complex antigens as a tool in serodiagnosis of kala-azar. Mol. Cell. Biochem. 253: 191-198. [Medline]
  24. Rönnelid, J., A. Tejde, L. Mathsson, K. Nilsson-Ekdahl, B. Nilsson. 2003. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an Fc{gamma}RII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann. Rheum. Dis. 62: 37-42. [Abstract/Free Full Text]
  25. Mathsson, L., A. Tejde, K. Carlson, M. Höglund, B. Nilsson, K. Nilsson-Ekdahl, J. Rönnelid. 2005. Cryoglobulin-induced cytokine production via Fc{gamma}RIIa: inverse effects of complement blockade on the production of TNF-a and IL-10: implications for the growth of malignant B-cell clones. Br. J. Haematol. 129: 830-838. [Medline]
  26. Mathsson, L., J. Lampa, M. Mullazehi, J. Rönnelid. 2006. Immune complexes from rheumatoid arthritis synovial fluid induce Fc{gamma}RIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-{alpha} by peripheral blood mononuclear cells. Arthritis Res. Ther. 8: R64[Medline]
  27. Mullazehi, M., L. Mathsson, J. Lampa, J. Rönnelid. 2006. Surface-bound anti-type II collagen containing immune complexes induce production of TNF-a, IL-1beta and IL-8 from peripheral blood monocytes via Fc{gamma}RIIa: a potential patho-physiological mechanism for humoral anti-collagen type II immunity in RA. Arthritis Rheum. 54: 1759-1771. [Medline]
  28. Duarte, M. I., M. R. Silva, H. Goto, E. L. Nicodemo, V. Amato Neto. 1983. Interstitial nephritis in human kala-azar. Trans. R. Soc. Trop. Med. Hyg. 77: 531-537. [Medline]
  29. Chaigne, V., Y. Knefati, R. Lafarge, J. Bronner, B. Mc Gregor, D. Fouque, J. C. Sabatier. 2004. Leishmaniose viscerale autochtone avec insuffisance renale aigue par glomerulonephrite infectieuse. Nephrologie 25: 179-183. [Medline]
  30. Kumar, P. V., Y. Daneshbod, A. Sadeghipoor. 2004. Leishmania in the glomerulus. Arch. Pathol. Lab. Med. 128: 935-936. [Medline]
  31. Naito, T., H. Yokoyama, K. J. Moore, G. Dranoff, R. C. Mulligan, V. R. Kelley. 1996. Macrophage growth factors introduced into the kidney initiate renal injury. Mol. Med. 2: 297-312. [Medline]
  32. Kitching, A. R., X. R. Huang, A. L. Turner, P. G. Tipping, A. R. Dunn, S. R. Holdsworth. 2002. The requirement for granulocyte-macrophage colony-stimulating factor and granulocyte-colony-stimulating factor in leukocyte-mediated immune glomerular injury. J. Am. Soc. Nephrol. 13: 350-358. [Abstract/Free Full Text]
  33. Miles, S. A., S. M. Conrad, R. G. Alves, S. M. Jeronimo, D. M. Mosser. 2005. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J. Exp. Med. 201: 747-754. [Abstract/Free Full Text]
  34. Hoogstraal, H., D. Heynemann. 1969. Leishmaniasis in the Sudan Republic 30: final epidemiological report. Am. J. Trop. Med. Hyg. 18: 1091-1210.
  35. Pontes-de-Carvalho, L. C., J. Lannes-Vieira, S. Giovanni-de-Simone, B. Galvao-Castro. 1986. A protein A-binding, polyethylene glycol precipitation-based immunoradiometric assay: application to the detection of immune complexes and C3 in human sera and of private antigens in cross-reacting parasite extracts. J. Immunol. Methods 89: 27-35. [Medline]
  36. Tejde, A., L. Mathsson, K. Nilsson Ekdahl, B. Nilsson, J. Rönnelid. 2004. Immune complex stimulation of peripheral blood mononuclear cells result in enhancement or suppression of IL-12 production dependent on serum factors: role of complement activation. Clin. Exp. Immunol. 137: 521-528. [Medline]
  37. Vely, F., N. Gruel, J. Moncuit, O. Cochet, H. Rouard, S. Dare, J. Galon, C. Sautes, W. H. Fridman, J. L. Teillaud. 1997. A new set of monoclonal antibodies against human Fc{gamma}RII (CD32) and Fc{gamma}RIII (CD16): characterization and use in various assays. Hybridoma 16: 519-528. [Medline]
  38. Van Den Herik-Oudijk, I. E., N. A. Westerdaal, N. V. Henriquez, P. J. Capel, J. G. Van De Winkel. 1994. Functional analysis of human Fc {gamma} RII (CD32) isoforms expressed in B lymphocytes. J. Immunol. 152: 574-585. [Abstract]
  39. Carvalho, E. M., B. S. Andrews, R. Martinelli, M. Dutra, H. Rocha. 1983. Circulating immune complexes and rheumatoid factor in schistosomiasis and visceral leishmaniasis. Am. J. Trop. Med. Hyg. 32: 61-68. [Abstract/Free Full Text]
  40. Loveday, C., J. S. Bingham. 1993. Changes in circulating immune complexes during the Jarisch Herxheimer reaction in secondary syphilis. Eur. J. Clin. Microbiol. Infect. Dis. 12: 185-191. [Medline]
  41. Elshafie, A., G. Elghazali, J. Rönnelid, P. Venge. 2006. Cystatin C as a marker of immune complex-associated renal impairment in a Sudanese population with visceral leishmaniasis. Am. J. Trop. Med. Hyg. 75: 867-868.
  42. Lopez, R., R. Lucena, M. Novales, P. J. Ginel, E. Martin, J. M. Molleda. 1996. Circulating immune complexes and renal function in canine leishmaniasis. Zentralbl. Veterinarmed. B. 43: 469-474. [Medline]
  43. Ghalib, H. W., M. R. Piuvezam, Y. A. Skeiky, M. Siddig, F. A. Hashim, A. M. el-Hassan, D. M. Russo, S. G. Reed. 1993. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. Clin. Invest. 92: 324-329. [Medline]
  44. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach, D. L. Sacks. 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507. [Medline]
  45. Padigel, U. M., J. P. Farrell. 2005. Control of infection with Leishmania major in susceptible BALB/c mice lacking the common {gamma}-chain for FcR is associated with reduced production of IL-10 and TGF-beta by parasitized cells. J. Immunol. 174: 6340-6345. [Abstract/Free Full Text]
  46. Buxbaum, L. U., P. Scott. 2005. Interleukin 10- and Fc{gamma} receptor-deficient mice resolve Leishmania mexicana lesions. Infect. Immun. 73: 2101-2108. [Abstract/Free Full Text]
  47. Gasim, S., A. M. Elhassan, E. A. Khalil, A. Ismail, A. M. Kadaru, A. Kharazmi, T. G. Theander. 1998. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin. Exp. Immunol. 111: 64-69. [Medline]
  48. Tan Sardjono, C., P. L. Mottram, P. M. Hogarth. 2003. The role of Fc{gamma}RIIa as an inflammatory mediator in rheumatoid arthritis and systemic lupus erythematosus. Immunol. Cell Biol. 81: 374-381. [Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elshafie, A. I.
Right arrow Articles by Rönnelid, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elshafie, A. I.
Right arrow Articles by Rönnelid, J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS